Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension
Clinical trial NCT00562614 · COMPLETED
Trial details
- NCT number
- NCT00562614
- Sponsor
- Retension Pharmaceuticals. Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-06-01
- Primary completion
- 2007-12-01
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.